The joint venture, Vescor, will develop molecule inhibitors of a number of protein targets at critical nodes of the autophagy development. Autophagy plays an important role during the development and maintenance of cancerous tumors, allowing the tumors to obtain nutrients for growth and survival.
Core research and development activities will take place at MD Anderson’s Institute for Applied Cancer Science.
The financial terms of the transaction, if any, have not been disclosed.
“Our goal is to drive novel drug discovery paradigms and develop cancer therapeutics targeting unexplored mechanisms that might provide high clinical impact. We are delighted to partner in this effort to advance novel drugs towards the clinic,” said Phil Jones, PhD, executive director of IACS.
More articles on transactions and valuations:
MultiCare, Navos affiliate to expand behavioral health services
HealthSouth, Memorial Hospital enter joint venture to operate rehabilitation hospital
DirectPath to purchase Wisconsin patient care company
